Is acotinib/acalatinib a targeted drug?

Acalabrutinib/Acalabrutinib is a targeted drug that belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors. BTK is an important signaling molecule that plays an important role in malignant tumors such as leukemia and lymphoma. By inhibiting the activity of BTK, acotinib blocks the proliferation and survival signaling pathways of malignant tumor cells.

Compared with traditional chemotherapy drugs, acotinib acts more selectively on malignant tumor cells and reduces damage to normal cells. This therapeutic strategy targeting specific signaling pathways is widely regarded as a precise, effective and safe approach to tumor treatment.

Acotinib is approved to treat certain types of lymphoma and leukemia. For example, it is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and small cell lymphoma (MCL). In these diseases, the BTK signaling pathway in malignant tumor cells is abnormally active, and the targeting effect of acotinib can effectively inhibit this abnormal activity.

As a targeted drug, acotinib can reduce the side effects and toxicity caused by traditional chemotherapy drugs and improve the quality of life of patients. Due to the highly selective effect of acotinib, it can better locate malignant tumor cells and reduce damage to normal cells. Acotinib has good clinical efficacy and can prolong the survival of patients.

However, like other medications, acotinib may have some side effects. Common side effects include fatigue, headache, gastrointestinal discomfort, etc. Therefore, before using acotinib, doctors will evaluate the patient's specific situation and closely monitor the patient's physical response during treatment.